Study Reveals Treatment Strategy for Triple-Negative Breast Cancer

Mateusz Opyrchal, MD, PhD, talks about how the Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells.

Mateusz Opyrchal, MD, PhD, of Roswell Park Cancer Institute in Buffalo, talks about a novel interaction between AURKA and the MAPK pathway in wild-type BRAF breast cancer cells and the cytotoxic effect of AURKA- and MEK1/2-specific inhibitors against estrogen-positive and triple-negative breast cancer cells.

Dr. Opyrchal gave a presentation at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.